EXEL Exelixis, Inc.

NASDAQ

$69.57

Exelixis, Inc. (EXEL) is expected to report earnings on January 28, 2027, after the market close. The consensus earnings estimate is $0.97 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.9% since its last earnings release on October 29, 2026.

Exelixis Reported In-line with Expectations, Reaffirms

Thursday, October 29, 2026 · 4:05 PM ET

4th Quarter, Dec 2026

Thursday · 4:05 PM ET

Earnings Whisper

-

vs $0.97 (GAAP)

Rev est $658.04M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $70.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Exelixis, Inc.

Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.